Novartis delivered strong H1 performance. FY 2020 guidance confirmed at higher end for core operating income and lower end for sales.

  • Due to COVID-19 first half results are more representative of underlying performance than Q2, sales growth of 6%  (cc1, +3% USD) and core¹ operating income growth of 19% (cc, +14% USD):
    • Innovative Medicines grew sales 7% (cc, +5% USD) and core operating income 16% (cc, +11% USD)
    • Sandoz grew sales 1% (cc, -2% USD) and core operating income 26% (cc, +19% USD)
  • Net sales in Q2 from continuing operations2 declined 1% (cc, -4% USD) largely reversing forward purchasing from Q1:
    • Key …
/by

Novartis delivered strong H1 performance. FY 2020 guidance confirmed at higher end for core operating income and lower end for sales.

  • Due to COVID-19 first half results are more representative of underlying performance than Q2, sales growth of 6%  (cc1, +3% USD) and core¹ operating income growth of 19% (cc, +14% USD):
    • Innovative Medicines grew sales 7% (cc, +5% USD) and core operating income 16% (cc, +11% USD)
    • Sandoz grew sales 1% (cc, -2% USD) and core operating income 26% (cc, +19% USD)
  • Net sales in Q2 from continuing operations2 declined 1% (cc, -4% USD) largely reversing forward purchasing from Q1:
    • Key products …
/by

Novartis launches first-of-its-kind not-for-profit portfolio of medicines for symptomatic treatment of COVID-19

  • Portfolio of 15 generic and over-the-counter (OTC) medicines from Sandoz division addresses urgent unmet needs of low- and lower-middle-income countries to treat patients with COVID-19 symptoms
  • Portfolio will be sold at zero-profit to governments in up to 791 eligible countries during the pandemic and until a vaccine or curative treatment is available
     
  • Early access to treatment for managing  COVID-19 symptoms is critical to preventing healthcare system overload

Basel, July 16, 2020 — …

/by

Novartis Phase III IRIDIUM data in Lancet Respiratory Medicine show benefit of Enerzair® Breezhaler® (QVM149), the first-in-class inhaled LABA/LAMA/ICS combination in uncontrolled asthma

  • Once-daily Enerzair® Breezhaler® (QVM149; IND/GLY/MF) was superior to once-daily IND/MF (QMF149) in improving the lung function of patients whose asthma is uncontrolled with LABA/ICS standard-of-care treatment1
     
  • In secondary analyses, improvements in lung function were observed with high- and medium-dose IND/GLY/MF compared to high-dose Sal/Flu1
     
  • In other secondary analyses, clinically meaningful reductions in moderate-to-severe (36%) and severe (42%) asthma exacerbation rates were observed with high- …
/by

Cancer didn’t stop for COVID-19

Throughout Myriam Mendila’s life, cancer has been ever-present. When she was only 8 years old, breast cancer took her mother. Later, her sister was diagnosed with the disease, and Mendila watched dear friends weather cancer odysseys of their own.

Witnessing the enduring impact of the disease is what inspired Mendila – now Chief Medical Officer and Global Head of Medical Affairs at Novartis Oncology – to dedicate her professional life to helping find potential treatments for people with cancer. It’s also what made her well aware that, while so much of the world stopped for COVID-19, …

/by

Novartis receives EC approval for Enerzair® Breezhaler®, including the first digital companion (sensor and app) that can be prescribed alongside a treatment for uncontrolled asthma in the EU

  • European Commission approves once-daily Enerzair® Breezhaler® (QVM149; IND/GLY/MF) in the EU, the first-in-class LABA/LAMA/ICS fixed-dose combination for patients whose asthma is uncontrolled with LABA/ICS1*
     
  • Optional digital companion with sensor and app that provide inhalation confirmation, medication reminders and access to objective data to better support therapeutic decisions also covered by EC approval
     
  • Approval based on robust …
/by

Novartis resolves legacy litigation matters, finalizing settlement of speaker program litigation with Government in the US and positioning company for the future by fully scaling its next-generation digital engagement technologies

  • Company finalizes USD 678 million settlement relating to suit challenging speaker programs and other promotional events conducted from 2002 through 2011 in the US as well as USD 51.25 million related to the company’s support of certain independent charitable co-pay foundations from 2010 to 2014
  • As part of these settlements, Novartis has agreed to new corporate integrity obligations in the US through 2025
  • Novartis embarks on new approach to meet the educational needs of physicians by setting new standard through digitally enabled education programs …
/by

Sandoz reviewing options after Federal Circuit upholds lower court ruling in biosimilar Erelzi® case

  • Sandoz evaluating next steps, including potential appeal to US Supreme Court
     
  • Ruling continues to prevent launch of important, affordable treatment option for US patients affected by chronic autoimmune and inflammatory diseases
     
  • Sandoz remains deeply committed to making Erelzi available to US patients as soon as possible, contributing to a more sustainable healthcare system

Holzkirchen, Germany, July 1, 2020 – Sandoz, a Novartis division and a global leader in biosimilars, today announced that the US …

/by

Novartis announces MET inhibitor Tabrecta™ approved in Japan for advanced non-small cell lung cancer with METex14

  • Tabrecta demonstrated an overall response rate of 68% and 41% in treatment-naive and previously treated non-small cell lung cancer (NSCLC) patients with MET exon 14 skipping (METex14) respectively
     
  • Lung cancer is the most common type of cancer in Japan and approximately 3,000 patients are diagnosed with METex14 metastatic NSCLC, a particularly aggressive form of the disease, in Japan each year1-2
     
  • Japan follows US approval earlier this year and demonstrates the company’s commitment to reimagining medicine for lung cancer …
/by

Novartis receives simultaneous approval for five new products from Japanese Ministry of Health, Labour and Welfare, offering Japanese patients a broad range of novel treatment options

Basel, June 29, 2020 — Novartis Pharma K.K. (“Novartis Pharma”) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) simultaneously approved five new treatment options for Japanese patients:

  • Tabrecta™ (capmatinib, formerly INC280), an oral MET inhibitor for MET exon 14 skipping (METex14) mutation-positive advanced and/or recurrent unresectable non-small cell lung cancer (NSCLC),
  • Entresto® (sacubitril valsartan sodium hydrate) in chronic heart failure,
  • Mayzent® (siponimod fumaric acid …
/by